In The News,

ADVI’s Vice President, Dr. Michael Kolodziej, talked to The American Journal of Managed Care about the side effects of first-gen BTK inhibitors

[el-text]

Written by Maggie L. Shaw

***excerpt***

“The thinking is that the reduced cardiovascular side effects, the reduced bleeding, are going to allow a better persistence on the second-generation drugs”

***end excerpt***

[/el-text]

View full article here